A phase II, randomised, double-blind, parallel-group, placebo-controlled trial to assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blastocyst transfer resulting from donor oocyte IVF/ICSI
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Sodium tungstate (Primary)
- Indications Infertility
- Focus Proof of concept; Therapeutic Use
- Acronyms OXOART 2
- Sponsors Oxolife
- 08 Jul 2024 According to an Oxolife media release, results of the Phase 2 trial are due to be published soon in the highly-regarded journal Human Reproduction.
- 08 Jul 2024 Results published in an Oxolife media release
- 08 Jul 2024 According to an Oxolife media release, company today presents successful phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction and Embryology (ESHRE) 40th Annual Meeting held in Amsterdam.